↓ Skip to main content

Dove Medical Press

Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2009
Altmetric Badge

Mentioned by

wikipedia
2 Wikipedia pages

Citations

dimensions_citation
66 Dimensions

Readers on

mendeley
48 Mendeley
Title
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety
Published in
Therapeutics and Clinical Risk Management, September 2009
DOI 10.2147/tcrm.s5189
Pubmed ID
Authors

Christoph Kellinghaus

Abstract

Lacosamide (LCM) is a novel agent that has been developed as an antiepileptic drug. In vitro studies suggest that LCM modulates voltage-gated sodium channels by enhancing their slow inactivation. In addition, LCM seems to interact with collapsin-response mediator protein 2 and thus may mediate neuronal plasticity. LCM has an elimination half-life of 13 hours, no relevant protein binding, and does not induce or inhibit enzymes of the cytochrome P450 system. No clinically significant drug-drug interactions have been discovered as yet. Experimental data suggest anticonvulsant as well as analgesic effects. Large clinical studies have demonstrated its efficacy for treatment of patients with partial seizures. LCM is well tolerated, and the most common adverse events are unspecific central nervous system and gastrointestinal effects such as dizziness, vertigo, nausea, and headache. LCM is approved for treatment of partial seizures with or without secondary generalization in the United States and the European Union within a dose range of 200 to 400 mg per day, administered twice daily. In addition to the oral formulations, an intravenous infusion solution is available.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 2%
Romania 1 2%
Unknown 46 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 23%
Student > Master 7 15%
Other 5 10%
Student > Doctoral Student 4 8%
Student > Ph. D. Student 4 8%
Other 12 25%
Unknown 5 10%
Readers by discipline Count As %
Medicine and Dentistry 23 48%
Neuroscience 8 17%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Nursing and Health Professions 1 2%
Agricultural and Biological Sciences 1 2%
Other 4 8%
Unknown 7 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2016.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#461
of 1,323 outputs
Outputs of similar age
#36,363
of 102,318 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 12 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 102,318 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.